No Data
No Data
Mengke Pharmaceuticals (688373.SH): 13.4044 million shares of the first public offering of restricted shares will be listed and traded on July 15th.
Mengke Pharmaceutical Co., Ltd. (688373.SH) announced that the stock will be listed as initial restricted shares. The stock subscription party...
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. MRX-8 not only
MicuRx Pharma's Phase 1 China Trial for Polymyxin Antibiotic Shows Good Safety Profile
Shanghai MicuRx Pharmaceutical's (SHA:688373) phase 1 trials for its MRX-8 polymyxin antibiotic injection showed a good safety profile in adult trial participants in China, according to a Wednesday fi
Mengke Pharmaceutical: The Phase I clinical trial of the independently developed antimicrobial drug MRX-8 in China has been successfully completed.
According to data from the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening situations due to drug-resistant infections every year. MRX-8 not only performs well in terms of safety and tolerance, but also demonstrates strong antibacterial activity against multidrug-resistant gram-negative bacteria, with significant clinical application potential. In China, the total number of days of antibiotic treatment for multidrug-resistant gram-negative bacterial infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3% during this period. Shanghai, June 5, 2024 / PRNewswire/ -
Mengke Pharmaceuticals (688373.SH): MRX-8 Phase I clinical trial in China has achieved expected targets.
On June 4th, Gelunhui reported that Mengke Pharmaceutical (688373.SH) announced that the Phase I clinical trial of the company's independently developed new injection of polymyxin antibiotics, MRX-8, has been completed recently and achieved the expected target in China. MRX-8 is a type of polymyxin antibiotics for injection, mainly used to treat infections caused by multidrug-resistant gram-negative bacteria. Traditional polymyxin antibiotics are clinically restricted because they can cause frequent kidney and neurotoxicity. MRX-8, as a new type of positively charged polypeptide drug of polymyxin antibiotics, is expected to maintain or improve the therapeutic effect with a careful structural design.
Mengke Pharmaceutical: Revenue of about 33.02 million yuan in the first quarter of 2024 increased 91.10% year-on-year
SHANGHAI, April 28, 2024/PRNewswire/ -- On the evening of April 25, the company released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 33.0161,000 yuan, an increase of 91.10% over the previous year; realized net profit to mother of 102.1366 million yuan; and total R&D investment of 84.646,900 yuan, an increase of 94.73% over the previous year. Evidence-based medical research continues to advance, accelerating the release of clinical potential. The company's first commercial product, contizolamide tablets, is a new generation of oxazolidinone antimicrobials independently designed and developed by the company, which can be used to treat complex skin and soft tissues
No Data